Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

Inclusion criteria (self-reported): * Adult (over the age of 18 years) * Diagnosed with HR+/HER2- metastatic breast cancer * Received at least 1 week of capivasertib + fulvestrant (Patients will be invited to provide documents demonstrating the use of capivasertib. Patients will be able to participate even if unable to obtain such documentation) Exclusion criteria (self-reported): * Patients who had discontinued capivasertib for more than 6 months before the date of the interview * Unable or unwilling to follow study procedures (including providing informed consent) * Not proficient in spoken English, as assessed by the moderator * Receiving capivasertib in a clinical trial setting * Patients who are not able to recall instruction for administration of capivasertib in a manner consistent with the labeling (e.g. 4 days on followed by 3 days off)